Publication:
Do We Have to Obtain Rebound Bilirubin Levels and What is the Optimal Time?

dc.contributor.authorMEMİŞOĞLU, ASLI
dc.contributor.authorÖZEK, EREN
dc.contributor.authorBİLGEN, HÜLYA SELVA
dc.contributor.authorÖZDEMİR, HÜLYA
dc.contributor.authorsOzdemir, Hulya; Bilgen, Hulya Selva; Memisoglu, Asli; Unkar, Zeynep Alp; Mutlu, Ali; Ozek, Eren
dc.date.accessioned2022-03-14T09:07:33Z
dc.date.accessioned2026-01-11T10:28:08Z
dc.date.available2022-03-14T09:07:33Z
dc.date.issued2019-03-01
dc.description.abstractAim: We aimed to determine the frequency of rebound hyperbilirubinemia (RHB) needing treatment and therefrom, to clarify the clinical importance of routinely checking serum total bilirubin (STB) levels after the cessation of phototherapy and to define an optimal time to check STB levels for the detection of RHB. Materials and Methods: Term and late preterm babies who received phototherapy were included in this study. The demographic and clinical features, time of onset of jaundice, phototherapy time and results to determine the etiology of jaundice were recorded for all babies. Serum rebound bilirubin measurements were performed two times at 12 and at 24 hours after the cessation of phototherapy. The re-initiation of phototherapy according to the 12th and 24th hour STB levels was accepted as early rebound and late rebound, respectively. IBM SPSS 22 was used for statistical analyses. Results: Data was available for 110 infants. The rebound rate requiring phototherapy was 9.1% (n = 10) and all had a risk factor. Most of the babies (9/10) rebounded at the 12th hour after the termination of phototherapy. Hemolysis and prematurity were found to be statistically significant for RHB (p = 0.008; p = 0.048). Conclusion: Post-phototherapy bilirubin follow-up may be incorporated using a combined approach of individualization, evaluation of risk factors, and application of common sense before discharge. Our study showed that STB levels could be measured after the cessation of phototherapy, especially in patients with a risk factor, at the 12th hour before discharge. Randomized controlled studies with larger sample sizes are still needed for definitive recommendations.
dc.identifier.doi10.4274/jpr.galenos.2019.03064
dc.identifier.issn2147-9445
dc.identifier.urihttps://hdl.handle.net/11424/242584
dc.identifier.wosWOS:000462579300003
dc.language.isoeng
dc.publisherGALENOS YAYINCILIK
dc.relation.ispartofJOURNAL OF PEDIATRIC RESEARCH
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHyperbilirubinemia
dc.subjectnewborn
dc.subjectphototherapy
dc.subjectrebound bilirubin
dc.subjectHYPERBILIRUBINEMIA
dc.subjectPHOTOTHERAPY
dc.subjectMANAGEMENT
dc.subjectINFANTS
dc.subjectTERM
dc.titleDo We Have to Obtain Rebound Bilirubin Levels and What is the Optimal Time?
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage11
oaire.citation.issue1
oaire.citation.startPage7
oaire.citation.titleJOURNAL OF PEDIATRIC RESEARCH
oaire.citation.volume6

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
192.05 KB
Format:
Adobe Portable Document Format